The efficacy of the AKT inhibitor Capivasertib is not uniform across all PTEN-deficient tumors. An analysis revealed that patients with 100% loss of the PTEN protein experienced the most significant benefit, with a 12-month improvement in radiographic progression-free survival. This highlights a direct correlation between the degree of protein loss and treatment response.

For high-risk, PTEN-deficient metastatic prostate cancer, a proposed strategy to maximize benefit while minimizing toxicity is sequential intensification. Clinicians can administer a triplet of ADT, an ARPI, and docetaxel first, and only after the chemotherapy course is complete, add the AKT inhibitor capivasertib to avoid severe, overlapping toxicities.

Oligometastatic prostate cancer accompanied by PTEN loss behaves aggressively and rapidly converts into polymetastatic disease or castration resistance. Dr. Neeraj Agarwal warns against being misled by low volume into using metastasis-directed radiation. Radiation trials lack large phase 3 confirmation and perform poorly in tumor suppressor gene mutations. Oncologists should proceed straight to aggressive systemic targeted therapy rather than wasting time arranging oligometastatic radiation.

The CAPItello-281 trial shows the benefit of the AKT inhibitor capivasertib is on a spectrum. Patients with 100% PTEN protein loss by IHC derive a much greater benefit than those with partial loss, suggesting a quantitative biomarker may optimize patient selection.

The approval of the AKT inhibitor Capivasertib has transformed PTEN testing from a prognostic tool for aggressive disease into a mandatory predictive test. Every patient with newly diagnosed metastatic prostate cancer should be assessed to determine eligibility for this targeted therapy, marking a significant shift in the standard of care.

Prostate cancer patients harboring PTEN loss often experience immediate pain reduction within one to two months of starting ADT plus ARPI doublet therapy. However, Dr. Neeraj Agarwal cautions that this symptom relief can be misleading: tumors with targetable alterations like PTEN deficiency or HRR mutations progress significantly faster. Oncologists must counsel patients not to forgo adding third-agent targeted therapy simply because their symptoms improved rapidly.

Exploratory analysis shows that while patients with 100% PTEN loss have a much worse natural history than those with 90% loss, the therapeutic effect of capivasertib is stable across this spectrum. The drug effectively targets the pathway regardless of the magnitude of loss, making it a robust option for this entire subgroup.

High-risk features in localized prostate cancer—such as lymph node positivity or T3 disease—strongly correlate with PTEN deficiency. Dr. Neeraj Agarwal preemptively orders PTEN testing at the locally advanced stage and secures insurance approval while tissue is readily available. If patients eventually develop metastatic disease, clinicians avoid losing crucial four-to-six-week turnaround windows waiting on biopsies and approvals before initiating targeted therapy like capivasertib.

The CAPItello-281 trial showed that the clinical benefit of adding the AKT inhibitor capivasertib is directly proportional to the degree of PTEN loss. The greatest separation in survival curves was seen in patients with 99-100% PTEN loss by IHC, suggesting the current trial entry cutoff of >90% may be too broad for optimal patient selection.